Disease · MONDO_0018908

non-Hodgkin lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. non-Hodgkin lymphoma. Diseases, record MONDO_0018908. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018908

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: non-Hodgkin lymphoma; Open Targets
Open Targets ID: MONDO_0018908; Open Targets
Other names: NHL, non-Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), non-Hodgkins lymphoma; Open Targets
Disease Ontology: DOID:0060060; Disease Ontology
MeSH: D008228; MeSH
NCI Thesaurus: C3211; NCI Thesaurus
Orphanet: ORPHA:547; Orphanet
Highest stage of its drugs: Approval, for 16 of its 492 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs492

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RITUXIMAB	CHEMBL1201576	Antibody	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	307	289	289	Drugs and targets
MELPHALAN	CHEMBL852	Small molecule	Approval	EMA Human Drugs	53	52	52	Drugs and targets
CARMUSTINE	CHEMBL513	Small molecule	Approval	EMA Human Drugs	45	44	44	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Approval	DailyMed	43	42	42	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Approval	DailyMed	34	33	31	Drugs and targets
PLERIXAFOR	CHEMBL18442	Small molecule	Approval	DailyMed and TTD	24	22	22	Drugs and targets
TOSITUMOMAB	CHEMBL1201604	Antibody	Approval	TTD	20	19	19	Drugs and targets
IDELALISIB	CHEMBL2216870	Small molecule	Approval	DailyMed and EMA Human Drugs	10	8	8	Drugs and targets
BENDAMUSTINE HYDROCHLORIDE	CHEMBL1201734	Small molecule	Approval	DailyMed	9	8	8	Drugs and targets
COPANLISIB	CHEMBL3218576	Small molecule	Approval	TTD	9	8	8	Drugs and targets

1 to 10 of 492

See all 492 drugs

Targets381

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MS4A1	B-lymphocyte antigen CD20	16	B-lymphocyte antigen CD20 binding agent; B-lymphocyte antigen CD20 cross-linking agent	Approval	https://conductscience.org/library/genes/931	Drugs and targets
PIK3CD	PI3-kinase class I	15	PI3-kinase class I inhibitor; PI3-kinase p110-delta subunit inhibitor	Approval	https://conductscience.org/library/genes/5293	Drugs and targets
TUBA1A	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/81027	Drugs and targets

1 to 10 of 381

See all 381 targets

Trials1,052

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 30 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00078949	Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma	Phase 3	849	2014-10-21	Lymphoma	CISPLATIN, CYTARABINE, DEXAMETHASONE, GEMCITABINE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00268203	Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma	Phase 2	765	2013-12-09	Lymphoma, Non-Hodgkin	TOSITUMOMAB	Its record names the disease	ClinicalTrials.gov
NCT00278408	Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	Phase 3	700	2025-08-26	Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, FILGRASTIM, PREDNISONE, RITUXIMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT01461928	A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab	Phase 3	692	2019-08-06	Non-Hodgkin's Lymphoma	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01296555	A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer	Phase 1	674	2024-07-31	Solid Cancers, Non-Hodgkin's Lymphoma	FULVESTRANT, LETROZOLE, TASELISIB	Its record names the disease	ClinicalTrials.gov
NCT02626455	Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)	Phase 3	551	2024-12-11	Lymphoma, Non-Hodgkin	BENDAMUSTINE, COPANLISIB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00075946	Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma	Phase 3	545	2015-06-22	Lymphoma	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01732926	Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas	Phase 3	475	2017-05-11	Indolent Non-Hodgkin's Lymphomas	IDELALISIB	Its record names the disease	ClinicalTrials.gov
NCT00345865	Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma	Phase 2	473	2020-07-14	Lymphoma	CARBOPLATIN, CARMUSTINE, CYCLOPHOSPHAMIDE, ETOPOSIDE, FILGRASTIM, IFOSFAMIDE, MELPHALAN, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00074490	Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers	Phase 2	442	2018-12-31	Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome	SIROLIMUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,052

See all 1,052 trials

Comparisons in its trials151

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Idelalisib + Bendamustine + Rituximab vs Placebo + Bendamustine + Rituximab: serious adverse events	229 of 317	58 of 155	472	NCT01732926	Trial comparisons
Ofatumumab vs Rituximab: Number of Participants With Complete Response (CR)	36 of 219	44 of 219	438	NCT01200589	Trial comparisons
Ofatumumab vs Rituximab: Number of Participants With Overall Response (OR)	110 of 219	144 of 219	438	NCT01200589	Trial comparisons
Ofatumumab vs Rituximab: Progression-free Survival (PFS) - Number of Participants With PFS Events	114 of 219	117 of 219	438	NCT01200589	Trial comparisons
Ofatumumab vs Rituximab: Number of Deaths	28 of 219	30 of 219	438	NCT01200589	Trial comparisons
Ofatumumab vs Rituximab: Number of Participants With Infusion Related Adverse Events Due to Study Drug	178 of 217	112 of 218	435	NCT01200589	Trial comparisons
Ofatumumab vs Rituximab: Number of Participants With Myelosuppression Adverse Events	24 of 217	41 of 218	435	NCT01200589	Trial comparisons
Ofatumumab vs Rituximab: Number of Participants With Infection Related Adverse Events	69 of 217	81 of 218	435	NCT01200589	Trial comparisons
Ofatumumab vs Rituximab: serious adverse events	38 of 217	37 of 218	435	NCT01200589	Trial comparisons
Mitoxantrone, Chlorambucil, Prednisolone (MCP) vs Rituximab + MCP: serious adverse events	20 of 177	18 of 183	360	NCT00269113	Trial comparisons

1 to 10 of 151

See all 151 comparisons in its trials

Papers from its trials492

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36344419	RESULT	1	PubMed
35271306	RESULT	1	PubMed
34296427	RESULT	1	PubMed
33152759	RESULT	1	PubMed
32552472	RESULT	1	PubMed
31738819	RESULT	1	PubMed
31029646	RESULT	1	PubMed
30957229	RESULT	1	PubMed
30953028	RESULT	1	PubMed
30850381	RESULT	1	PubMed

1 to 10 of 492

See all 492 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018908

GET https://conductscience.org/api/diseases/v1/MONDO_0018908/drugs?page=2

API reference For AI assistants